SCHEMBL1775201

SCHEMBL1775201

CSc1ncc(C(=O)O)c(Nc2ccc(Br)cc2N)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 4/20 0.42
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
RXFP1 Q9HBX9 2/20 0.41
THRB P10828 1/20 0.41
EGFR P00533 1/20 0.41
SYK P43405 2/20 0.40
KDM4E B2RXH2 2/20 0.40
GLA P06280 1/20 0.40
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
MAPK8 P45983 2/20 0.38
MET P08581 1/20 0.38
LMNA P02545 1/20 0.38
MAPK13 O15264 1/20 0.37
MAPK12 P53778 1/20 0.37
MAPK11 Q15759 1/20 0.37
MAPK14 Q16539 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1774779 0.87 MAPT (0.45) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL1773735 0.86 LMNA (0.46) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL1774655 0.85 MAPT (0.62) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL27745413 0.84 MAPT (0.43) MAPTALDH1A1SMN1; SMN2RXFP1THRB
SCHEMBL1773447 0.84 MEN1 (0.52) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL4702538 0.84 EGFR (0.39) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL2174057 0.83 MAPT (0.53) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL1773844 0.83 LMNA (0.49) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL1773691 0.82 MAPT (0.44) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL1773998 0.81 MAPT (0.45) MEN1KMT2AMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966212-B1 DIAZEPINONES MERCK PATENT GMBH (DE) 2015-05-13 EP disclosed
US-7943608-B2 Diazepinoes MERCK PATENT GMBH (DE) 2011-05-17 US disclosed
CN-101341151-A Diazepinones MERCK PATENT GMBH (DE) 2009-01-07 CN disclosed
US-20080318934-A1 Diazepinoes MERCK PATENT GESELLSCHAFT (DE) 2008-12-25 US disclosed
EP-1966212-A1 DIAZEPINONES Merck Patent GmbH (DE) 2008-09-10 EP disclosed
WO-2007079826-A1 DIAZEPINONES MERCK PATENT GMBH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318934-A1 Diazepinoes CDK1, MAP3K11, MAP3K1 MEN1 112/4885KMT2A 666/4885MAPT 904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.